Konakion 2 mg/0.2 ml (Injection)

Indications

• Prophylaxis and treatment of haemorrhagic disease in the newborn
• Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia
• Prevention and treatment of bleeding due to vitamin K deficiency

Pharmacology

• Procoagulant factor
• Component of a hepatic carboxylase system
• Involved in the post translational carboxylation of clotting factors
• Promotes synthesis of coagulation factors by the liver

Dosage & Administration

• Usual dose for Neonates is 2 mg orally at or just after birth
• Dose for Children over 1 year of age is 5-10 mg orally
• Initially, 1 mg by intravenous injection for therapy
• Special dose for Neonates with risk factors and pre-maturity

Interaction

• Antagonises the effect of coumarin-type anticoagulants
• Coadministration of anticonvulsants can impair the action of vitamin K-1

Contraindications

• Known hypersensitivity to any of its constituents

Side Effects

• Possible occurrence of anaphylactoid reactions
• Venous irritation or phlebitis after parenteral use of Konakion injections

Precautions & Warnings

• Careful monitoring of the coagulation parameters is necessary for patients with severely impaired liver function after administration of Konakion

Therapeutic Class

• Vitamin-K Preparations

Storage Conditions

• Keep below 30°C temperature
• Away from light & moisture
• Keep out of the reach of children

Related Brands

• Konakion 10 mg/ml (Injection) - radiant-pharmaceuticals-ltd
• K-One MM 2 mg/0.2 ml (Injection) - square-pharmaceuticals-plc